

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Organic Preparations and Procedures International

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t902189982>

Advances in the Synthesis of 5- and 6-Substituted Uracil Derivatives

Javier I. Bardagí^a; Roberto A. Rossi^a

^a INFIQC, Departamento de Química Orgánica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Ciudad Universitaria, Argentina

Online publication date: 20 November 2009

To cite this Article Bardagí, Javier I. and Rossi, Roberto A. (2009) 'Advances in the Synthesis of 5- and 6-Substituted Uracil Derivatives', *Organic Preparations and Procedures International*, 41: 6, 479 – 514

To link to this Article: DOI: 10.1080/00304940903378776

URL: <http://dx.doi.org/10.1080/00304940903378776>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Advances in the Synthesis of 5- and 6-Substituted Uracil Derivatives

Javier I. Bardagí and Roberto A. Rossi

INFIQC, Departamento de Química Orgánica, Facultad de Ciencias Químicas,
Universidad Nacional de Córdoba, Ciudad Universitaria, 5000 Córdoba,
Argentina

Introduction	480
I. Uracils with Carbon-based Substituents	481
1. <i>C(Uracil)-C(sp³) Bonds</i>	481
2. <i>C(Uracil)-C(sp²) Bonds</i>	491
3. <i>C(Uracil)-C(sp) Bonds</i>	498
4. <i>C(Uracil)-Heteroatom Bonds</i>	499
a. <i>C(Uracil)-N Bonds</i>	499
b. <i>Synthesis of 5,6-Halogen Derivatives</i>	501
c. <i>C(Uracil)-Other Heteroatom Bonds</i>	501
II. Fused Systems	501
1. <i>C5-C6 Polycyclic Uracils</i>	501
2. <i>Other Polycyclic Uracils</i>	508
III. Glossary	510
Acknowledgements	510
References	511

Advances in the Synthesis of 5- and 6-Substituted Uracil Derivatives

Javier I. Bardagí and Roberto A. Rossi

INFIQC, Departamento de Química Orgánica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Ciudad Universitaria, 5000 Córdoba, Argentina

Introduction

The uracil unit is one of the most important structures in life, being part of the building blocks of RNA and DNA and other natural products.¹ Therefore, it is not surprising that uracil derivatives have important biological activity. Uracil-based compounds are used in the treatment of cancer (5-fluorouracil) and against infections of the HIV virus (AZT). Actions as antiviral and antitumoral agents are perhaps the most widely reported activity. However, other uracil derivatives have been synthesized which are herbicides, insecticides, bactericides, acaricides, etc. In addition, uracil units can be found in the chemistry of peptide nucleic acid (PNA) or as part of other fused systems with antiallergic, antihypertensive, cardiotoxic, bronchodilator or antibronchitis activity.²

The search for uracil derivatives has been carried out since the beginning of the last century and even today there is great interest in the development of new derivatives and strategies for synthesis so as to improve the yield of known compounds. To prepare uracils, there are three main synthetic strategies: a) building the uracil nucleus from acyclic precursors with appropriate substituents; b) modification of the structure of functionalized uracils or uracil itself by reaction with different reagents, as illustrated by the recent synthesis of 5-trifluoromethyluracil³ and uridines with oxiranyl and tetrahydrofuranyl substituents;⁴ c) functionalization of masked uracil moieties with reactions incompatible with the nucleus, for example the synthesis of 6-aryl and 6-acyluracils⁵ and 2'-deoxypseudouridine.⁶ Combinations of these approaches are often found in the synthesis of target compounds with potential biological activities.

The present review will cover advances in the synthesis of 5- and 6-substituted uracils (*Figure 1*) over the last 8–10 years. It has been organized in terms of the type of union that links the uracil moieties to the substitution groups; fused systems will have a separate section.

Received June 23, 2009; in final form September 4, 2009.

Address correspondence to Robert A. Rossi, INFIQC, Departamento de Química Orgánica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Ciudad Universitaria, 5000 Córdoba, Argentina. E-mail: rossi@fcq.unc.edu.ar





Figure 1


I. Uracils with Carbon-based Substituents

1. C(Uracil)-C(sp³) Bonds

Chen *et al.* have synthesized 6-methyl (**3**) and 6-ethyluracils (**7**) using two different approaches as part of a study of polysubstituted uracils (Schemes 1 and 2). Uracil **3** was synthesized from a urea derivative **1** by reaction with diketene, to afford compound **2**, which after reflux in acetic acid afforded uracil **3** (57% from **1**).⁷ Later the authors developed a more efficient strategy by using diketene, trimethylsilyl chloride, and NaI in CH₃CN,⁸ obtaining **3** from **1** in one step in 95% yield.



Scheme 1



Scheme 2





Figure 2


6-Ethyluracil **7** was prepared from 1,3-dialkyl-6-chlorouracil **4** (Scheme 2)⁹ by reaction with the anion of diethylmalonate to give **5**; the treatment of **5** with NaH and MeI afforded **6**, which by hydrolysis and double decarboxylation induced by KOH gave **7** in 19% overall yield.

In a study of glutamate agonists and antagonists, Young and co-workers used their “ring switching” strategy to prepare a willardiine (Figure 2) isomer 2-(pyrimidin-2,4-dione-5-ylmethyl)-(2*S*)-glycine (**9**) from heterocycle **8** (Scheme 3).¹⁰



Scheme 3


A synthesis of 5-benzyluracils (**13**) from Baylis-Hillman adducts (**10**) was developed by Kim *et al.* (Scheme 4).¹¹ Substitution of acetate by primary amines gave **11** in moderated yield which afforded ureas **12** after treatment with R'NCO. Finally, in the presence of a base, **12** cyclized to afford uracil **13** in good yields.



Scheme 4


Batra *et al.* synthesized 1,5-disubstituted uracils **17** using the same approach with a slight modification using BrCN instead of R'NCO (Scheme 5).¹²

Recently, Cao and Huang developed a solid-phase synthetic strategy for the synthesis of uracil and 6-methyluracils bonded to different heterocycles through N1 or N3, starting from




Scheme 5

α,β -unsaturated esters and amines.¹³ A selenopolystyrene resin was used and good yields (41–75%) and moderate to good purity (64–96%) were obtained (Scheme 6). However, the inclusion of larger group at 6-position, like aryl or isopropyl, was not possible. As a result, this strategy seems to be an excellent option for variation of N1 and N3 substituent but it has a very limited utility in the synthesis of C5 or C6 derivatives.



Scheme 6

Yano *et al.* have synthesized a family of 6-methylene-bridged uracil derivatives,^{14,15} in the search for an inhibitor of thymidine phosphorylase (TP) better than 6-amino-5-chlorouracil, a known TP inhibitor. The authors were indeed able to obtain a more potent inhibitor of TP and with better properties (solubility and oral absorption). The synthesis of the aminomethyluracils (**19**) was accomplished through the reaction 5-halo-6-chloromethyluracils (**18**) with the appropriate amines (Scheme 7). Most of the reactions were carried with the amine in water as solvent and the yield obtained ranged from very low (1%) to excellent (93%); however, some reactions were not optimized in order to obtain the best yields possible. More than twenty-five amines were used, including acyclic and cyclic ones, diamines and aminoalcohols, among others.




Scheme 7

Later on Corelli *et al.* published their microwave (MW) assisted synthesis of the same type of compounds in methanol as solvent,¹⁶ starting from **18** (R = H, X = Cl)


by reaction with different amines. Uracil **19a** ($R^1 = H$; $R^2 = (CH_2)_2NH_2$) was prepared from the protected **19b** ($R^1 = H$; $R^2 = (CH_2)_2NH\text{-Boc}$). Derivative **19c** ($R^1 = H$; $R^2 = (CH_2)NHC(NH)NH_2$) was also prepared from **19a** by reaction with *S*-methylisothiourea.

A series of guanidine, amidino and thioureido derivatives were synthesized from 6-aminomethyl-5-chlorouracil under different conditions (Scheme 8).¹⁵




Scheme 8

5-Dihydropyrimidineuracils (**21**) were synthesized by Knaus and co-workers¹⁷ from 5-formyluracil (**20**) using a three-component Hantzsch reaction (Scheme 9).




Scheme 9

Looking for a convenient synthesis of monofluorinated alkyluracils, Kung and co-workers have developed a direct alkylation of nucleosides at the 5-position.¹⁸ A Pd-catalyzed Negishi cross-coupling reaction of **22** and unactivated monosubstituted alkylzinc bromides (**23**) was used to prepare 5-alkyluracils **24** with moderate yield carrying -F (43–53%), esters, -CN, -OSiR₃ (29–39%) functional groups (FG) (Scheme 10). However, the method has the limitation of providing low yields of products (0–8%) when the alkyl chain is short (propyl, ethyl).



Scheme 10


Kumar *et al.* employed an indium catalyst to prepare the 5-substituted uracils (**26** and **28**) from 5-formyluracils (**25**) and from the Schiff bases of **25** (Schemes 11 and 12).¹⁹ Allylation of **25** with bromoallyl compounds in the presence of indium metal in a mixture of THF:H₂O (1:1) gave compound **26** in moderate to good yields (Scheme 11); diastereomeric



Scheme 11


ratios of >99:1 were obtained in the best case. They suggest that the high diastereoselectivity of the reaction results from the complexation of the C-4 carbonyl oxygen of the uracil.

From the Schiff bases **27a**, amines **28a** were obtained in 68–70% yield. The authors were able to obtain a moderate yield and good diastereocontrol of uracil **28b** derived from chiral R^2 (**27b**) (Scheme 12).




Scheme 12

More recently, Vasella *et al.* have used 6-(diazomethyl-1,3-bis(methoxymethyl)uracil **29** (see Scheme 34) to prepare 6-substituted uracil **30** (Scheme 13) by reactions with thiophene through a Rh(II) catalyst.²⁰




Scheme 13

The synthesis of tetrasubstituted uracils from one alkyne and two isocyanates using a Ni(0) catalyst was reported by Duong and Louie.²¹ They optimized the conditions to prepare 5-TMS-6-alkyl (methyl, *t*-butyl and *i*-propyl) uracils **31** in good yields (Scheme 14). The proposed mechanism involves an oxidative coupling between a molecule of alkyne and isocyanate which gives the nickel intermediate **32** (Scheme 15). Reaction with another




Scheme 14



Scheme 15

molecule of isocyanate is suggested to give compound **33** which, after reductive elimination, gives uracil products **31** and the Ni(0) catalyst which continues the catalytic cycle.


In search for new uracil derivatives, Saladino *et al.* synthesized a series of uracil and uridines with oxiranyl and tetrahydrofuranyl substituents (Schemes 16–19) and evaluated their biological activity toward the Sendai virus, finding potent and selective antiviral activity.⁴ The authors used a metalation-alkylation sequence developed previously²² from **34**, which gave the anion **34**[−] when treated with lithium diisopropylamide (LDA), and then the anion trapped with α -chloroketones **35** giving the oxiranyl methyl uracils **36** (Scheme 16).




Scheme 16

The reaction of lithium enolate **34**[−] (R = Me) with γ -chloroketones gave tetrahydrofuranylmethyl uracils (**37**); however, the yields were low (Scheme 17). The reaction of **34**[−] (R = glycoside) with 3-chloropropyl methyl ketone afforded **38** in modest yield.

With a similar approach, uracil precursor **39** afforded oxiranylmethyl derivative **40** and tetrahydrofuranylmethyl analogues **41** (Scheme 18).




Scheme 17



Scheme 18


The use of 6-chloromethyl-1,3-dimethyluracil (**42**) instead of **39** allowed the preparation of 6-oxiranyl uracils **43** in acceptable yields after reaction with ketones (Scheme 19).



Scheme 19


Lithiation of 5-iodo-2'-deoxyuridine sodium salt was accomplished by Suemune *et al.* to give compound **44**, used to prepare different 5-substituted-2'-deoxyuridines (**45**) in good yield by reaction with MNP, CH₃I, CD₃OD, TMSCl, PhCHO and CH₃SSCH₃ as electrophiles (E⁺, Scheme 20).²³

Reese and Wu⁶ synthesized 5-(2-deoxy-β-D-ribofuranosyl)-2,4-dioxypyrimidine (2'-deoxypseudouridine, **49**) as part of a study oriented to the synthesis of monomers for the antigen approach to oligonucleotide-based chemotherapy. In contrast to other synthesis of **49**, 2-deoxy-D-ribose was used as the source of the sugar to prepare lactone **47** (Scheme 21).



Scheme 20

Compound **46** was lithiated and allowed to react with **47** giving an acyclic compound, which after reduction and cyclization (under Mitsunobu conditions) afforded the protected product **48**. The latter compound was deprotected to yield **49**.




Scheme 21


(-)-7-Epiculindospermopsin (**57**) is an example of a complex 6-substituted uracil derivative; the total synthesis of this compound was developed by White and Hanses.²⁴ They used a masked uracil nucleus, 2,4-dimethoxypyrimidine, which gave the uracil in the penultimate step of the synthesis. The synthesis of **57** was developed from barbituric acid in 23 steps (0.6%). The authors proposed the synthesis of **57** from two fragments **53** and **54** (Scheme 22). Synthesis of **53** started with the preparation of 4-bromo-2,6-dimethoxypyrimidine **50** from barbituric acid (83%). Compound **50** was then lithiated and allowed to react with **51** to give **52** in 97% yield, then **52** was transformed to **53** in 7 steps (34% from **52**). The reaction of **53** and **54** afforded **55** in 60% yield. The nitrile oxide was transformed to **56** in 13 steps in 3.8% yield, the last step being the deprotection of the uracil with HCl. Finally, sulfation of **56** gave **57** (63%).

Boudet and Knochel used an improved bromine/magnesium exchange of 5-bromo-6-halo-2,4-dimethoxypyrimidine (**58**) to prepare 5,6-disubstituted uracils.²⁵ The use of one equivalent of the magnesium reagent gave a regioselective substitution of the halogen in position 5, affording 6-halo-5-substituted-2,4-dimethoxypyrimidines (**59**) with good yields (70–91%) by reaction with different electrophiles (E^{1+}), such as aldehydes, acyl chlorides, allyl and benzyl bromide, TMSCl, and TsCN (Scheme 23). Access to 5,6-substituted uracils **60** was possible in two successive steps (69–81%) without the need to isolate **59**.

Oxypurinol **61** and emyvirine **62** (Scheme 24) were prepared as an application of this methodology, where hydrolysis with HCl in MeOH at reflux was used to convert the 2,4-dimethoxypyrimidines into uracils.



Scheme 22




Scheme 23



Scheme 24


In the same type of studies with magnesium compounds, Kopp and Knochel synthesized uracils without the need to protect the acidic proton of uracil (Scheme 25).²⁶ They prepared the tri-anion **64** from 5- and 6-iodouracils **63** and allowed it to react with different electrophiles (aldehydes, bromides, alkenes) obtaining good yields of the substitution products **65** (Scheme 25). The authors were able to synthesize a precursor (**65**) of emivirine **62** (X = *i*-Pr, Y = CH₂Ph).



Scheme 25


Perfluoroalkyl derivatives are an important class of the family of uracil compounds because of the special properties provided by fluoro atom. Compared to the synthesis of alkyl derivatives, perfluoro derivatives have been less explored, probably due to the difficulties found in the chemistry of perfluoroalkylated compounds.

Savéant *et al.* have used an electrochemically-induced $S_{RN}1$ reaction to prepare 5-perfluoroalkyluracils in moderate yield (Scheme 26).²⁷




Scheme 26

Strekowski *et al.*²⁸ synthesized 5-perfluoroalkyluracils **67** from 5-bromo-2,4-diethoxyuracil (**66**) and iodoperfluoroalkanes in two steps (Scheme 27). They used a known procedure which utilized a Cu-Bronze reagent to prepare uracils **67** with better yield than those previously reported.²⁹



Scheme 27

6-Perfluoroalkyluracils and thiouracils (3-aryl and 3-alkyl) have been prepared from esters, perfluorinated nitriles, and isothiocyanates (Scheme 28).³⁰ The first step of the synthesis involves the reaction of the enolate of ester **68** with the nitriles to give fluorinated β -enamino esters (**69**), which after treatment with NaH, reacts with iso- and isothiocyanates to afford uracils **70** in good yields. The methodology seems to be useful to prepare even 5,6-disubstituted uracils.




Scheme 28

The good results obtained encouraged the authors to perform the synthesis of the same compounds through a solid-phase approximation. Linking the ester to a Wang resin ($\text{R} = \text{resin}$ in *Scheme 28*) they were able to prepare 3-aryl- and 3-alkyl-6-(difluorophenylmethyl)uracils in good yields (67–89%) with moderate to very good purity (65–99%); thiouracils were also prepared, but the yields and purity were lower (55–63% and 61–73%).³⁰

The fluorous synthesis with tagged ester ($\text{R} = \text{R}_f$, *Scheme 27*) was accomplished more recently.³¹ The uracils **70** ($\text{R}^1 = \text{H}$, $\text{R}_f = \text{CF}_2\text{CH}_2\text{CH} = \text{CH}_2$, $\text{R}^2 = \text{aryl, alkyl}$) were obtained with good yields (52–99%).


Recently, 5-trifluoromethyl uracils were synthesized from uracil and CF_3I in modest to excellent yields using a catalytic system of FeSO_4 , H_2O_2 and H_2SO_4 .³ The authors were able to scale the synthesis to the use of 40 Kg of uracil. Using this approach to prepare 5-trifluoromethyl derivatives from substituted uracils was also successful (*Scheme 29*).



Scheme 29


2. C(Uracil)-C(sp²) Bonds

The synthesis of 5-methyl-1,6-diphenyluracil and 5-methyl-6-phenyl-1-(phenylmethyl)uracil (**72**) was performed from the Baylis-Hilman adducts **10** described in Section I.1) (*Scheme 4*) through cyclization of the urea **71** (*Scheme 30*).¹¹



Scheme 30


Searching for a rapid and economical screening of inhibition of human deoxyuridine triphosphate nucleotidohydrolase (dUTPase) and human nuclear uracil DNA glycosylase (UNG2), Stivers *et al.* developed a strategy to prepare *tris*-uracil oximes from oxyamine **73**, 5-formyluracil (**74**) and aryl aldehydes (Scheme 31).³² The synthesis involved reaction in DMSO at 37°C; a mixture of the homotrimeric (**75** and **76**) and heterotrimeric (**77** and **78**) compounds were obtained. More than two hundred aryl aldehydes were used and the mixtures were screened for active compounds without purification of the mixtures.



Scheme 31

As part of a study on the reactions of metal (Cr, W) carbene complexes, Ricart *et al.* synthesized monoalkyl (1 or 3) and 1,3-dialkyl-6-phenyluracils *via* reaction of carbenes **79** with substituted ureas, followed by oxidation of the metal carbonyl complex **80** to **81** (Scheme 32).³³⁻³⁵


The synthesis of complexes **80** was accomplished at room temperature under MW irradiation with good yields that were better than with conventional heating,^{33,34} with shorter reactions times (days to hours) and allowing the reactions to be performed, in some cases, without solvent. The authors studied several oxidants³⁵ to transform **80** into **81** and



Scheme 32


found that the use of TABF open to air³⁶ and *t*-butyl hydroperoxide were the most generally useful reagents.

Using Ni(0) as catalyst (see Scheme 14), Duong and Louie²¹ prepared 6-carbonyl and 6-vinyl-5-(trimethylsilyl)uracils (**82**) from one alkyne and two isocyanates (Scheme 33) in moderate yields (38–43%). Although the synthesis of 5,6-diphenyl derivatives was not possible, the stannane **82** ($R^1 = SnBu_3$, $R^2 = methyl$, $R = ethyl$) was prepared using this approach and reaction with PhI in a Stille reaction ($Pd(PPh_3)_4$, CuI, DMF 60°C), gave 6-methyl-5-phenyl-1,3-diethyluracil in 75% yield in the two steps.




Scheme 33

Recently, Vasella *et al.* have prepared a versatile 6-diazomethyluracil derivative **29** (Scheme 34).²⁰ The synthesis started with 6-formyl-1,3-dimethoxymethyluracil (**83**) which, after reaction with NH_2NH_2 , gave hydrazone **84** in 84% as a mixture of *E/Z* isomers in a ratio of 9:1. This mixture was allowed to react with MnO_2 to give compound **29** in 90% yield.



Scheme 34


Reactions of compound **29** in the presence of $Rh(OAc)_2$ in CH_2Cl_2 afforded dimeric compounds **85** as a mixture of *Z* (45%) and *E* (22%) isomers (Scheme 35) through the formation of carbenoids. Deprotection of **85** with BBr_3 gave diuracil **86** in moderate yield (*Z* (52%) and *E* (58%)).



Scheme 35

Reactions induced by $\text{Rh}(\text{OAc})_2$ in the presence of different carbenophiles afforded 6-substituted and fused compounds (see *Scheme 13* and *Scheme 70–72*). When 2-styrylfuran was used as the carbenophile, ketone **87** was obtained as a mixture of four *E/Z* isomers. However when the reaction was allowed to equilibrate during seven days, it afforded (*E,E,E*)-**87** in 60% (*Scheme 35*).

From 2003 to 2005, a series of polysubstituted uracils were synthesized by Chen *et al.* in a study of gonadotropin receptor antagonists. They used a Pd-catalyzed Suzuki-Miyaura reaction to synthesize 5-aryloracils (**89**) from 5-halouracils (**88**) (*Scheme 36*). Aldehyde, amino, methylaryl as well as chiral structures were used as substituents in positions 1 and 3 in substrate **88**. Boronic acids or pinacol esters of 1-naphthyl, 2-dibenzofuranyl³⁷ and phenyl with OCH_3 , OH , OCF_3 , OPh , alkyl,^{37,38,39} F, Cl, SCH_3 , OR and alkenyl groups as substituents^{37,39} were used to obtain moderate to good product yields.




Scheme 36

Agrofolgio *et al.*⁴⁰ have developed a strategy to prepare 5-(2-furyl) and 5-(2-thiophenyl) acyclo-nucleosides (**89**, $\text{R}^1 = \text{acyclic diol}$, $\text{R}^2 = \text{R}^3 = \text{H}$) from 5-iodouracil. They used a catalytic system ($\text{Pd}(\text{OAc})_2$, AsPh_3 , K_2CO_3 in THF) to introduce the aryl moiety and the products were obtained in good yields (68–94%). The synthesis with an alkenyl boronic acid ($\text{RCH} = \text{CH}_2\text{B}(\text{OH})_2$) was also tested (52–60%); however, the competition with a Heck reaction led to a mixture of isomers impossible to separate.

More recently, Pomeisl *et al.* employed the same approach to synthesize 5-aryl-1-(2-phosphomethoxy)ethyluracil (**89**, $\text{R}^1 = \text{CH}_2\text{CH}_2\text{OCH}_2\text{P}(\text{O})(\text{OR})_2$, $\text{R}^2 = \text{R}^3 = \text{H}$) with


moderate isolated yield (24–58%) using the boronic acids of 1-naphthyl, 2-phenylvinyl, 4-fluorophenyl, 3-nitrophenyl, 2-furyl, phenyl, 3- and 4-pyridyl.⁴¹

As part of a study within the development of labeled PNA, Oquare and Taylor used a Heck reaction to prepare (*E*)-3-(1-(2-*t*-butoxy-2-oxoethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)acrylic acid (**91**) from 1-(2-*t*-butoxy-2-oxoethyl)-5-iodouracil (**90**) (Scheme 37).⁴² This reaction was a key step in a synthesis of a PNA monomer derived from uracil, produced in 6 steps and 30% overall yield from commercial 5-iodouracil.




Scheme 37

The synthesis of 5-bromoacetyluracils **93** from **92** has been accomplished in 40% yield (Scheme 38) using a Stille reaction. The ultimate goal was the synthesis of 5-thiazolyluracils from **93** derivatives, but somewhat surprisingly, the yield of this transformation was not reported.⁸




Scheme 38

Mintas *et al.* have also used this strategy to prepare 5-aryl and 5-alkenyl uracils substituted with a derivative of L-ascorbic acid at N1.⁴³ They utilized tributylstannanes to obtain compounds **94** in 31–43% yield (Scheme 39).




Scheme 39

6-Aryl- and 6-acyluracils were recently synthesized from the commercially available 6-chloro-2,4-dimethoxypyrimidine (**95**).⁵ The photostimulated reaction of **95** with the anion $^-\text{SnMe}_3$ in liquid ammonia afforded stannane **96** in high yield through a $\text{S}_{\text{RN}}1$ reaction.⁴⁴ Compound **96** was employed in a Stille reaction with 1-iodonaphthalene affording pyrimidine **97** in good yields. Finally the target uracil **98** was obtained by hydrolysis in quantitative yield (Scheme 40).




Scheme 40

When the three steps ($\text{S}_{\text{RN}}1$ reaction-cross coupling reaction-hydrolysis) were performed in a one-pot reaction without the need to purify intermediates **96** and **97** (Scheme 41), 6-substituted uracils **99** (R = 1-naphthyl, 4-chlorophenyl, 3-chlorophenyl, 2,3,4,5,6-pentafluorophenyl) were isolated (43–57%) as pure products. When the electrophile was a benzoyl chloride (**99**, R = ArCO), 6-benzoyl (54%) and 6-(2-chlorobenzoyl) uracils (49%) were obtained as pure products.




Scheme 41

Koroniak *et al.* have synthesized pentafluoropropenyl uracils using an addition-elimination approach.⁴⁵ The (2,4-dimethoxypyrimidin-5-yl)lithium compound derived from **100** allowed the preparation of 5-pentafluoropropenyl-2,4-dialkoxy-pyrimidine (*E* and *Z* mixture, **101**) by reaction with commercial hexafluoropropene. Substitution at position 6 was possible from **101** (R = Et) instead of **100**, to give 5,6-dipentafluoropropenyl-2,4-diethoxypyrimidine; however, the yield was low (43%). Compound **101** (R = *t*-butyl) after hydrolysis gave uracil **102** in good yields (Scheme 42).




Scheme 42

From 1,3-dimethyl-5-substituted uracils (**103**) the authors were able to prepare 6-pentafluorouracil (**104**) with 47–59% yield for X = F, Me (Scheme 43)⁴⁵ but the reactions were not general, because no products were obtained from addition-elimination when X = H, Br, NO₂.




Scheme 43

Savéant *et al.*^{46,47} have synthesized 5-arylruracils (**106**) by the reaction of uracil anion (**105**) with aryl iodides, using an electrochemical approach (Scheme 44, see also Scheme 26). The reactions were postulated to occur through an S_{RN}1 reaction and the yields were moderate, where 1-imidazolyl and benzene compounds with NO₂, CN, COPh, CF₃, F as substituents were introduced.



Scheme 44


Using another electrochemical reaction Davarani *et al.*⁴⁸ have recently synthesized catechol-uracil derivatives (**109**) in very good yields from 6-aminouracils **107** and catechols **108** (Scheme 45). The reactions proceed through an electrochemical oxidation of catechols followed by a Michael addition and were regioselective, giving only substitution at position 4 of the catechols.



Scheme 45


3. C(Uracil)-C(sp) Bonds

The Sonogashira coupling of terminal alkynes has been used to obtain modified nucleosides.^{49, 50} Recently, Hudson *et al.*^{51, 52} adopted this approach to prepare 5-alkynyl derivatives with an ester group at N1 or as part of a PNA monomer (Scheme 46). The authors were able to prepare compounds **110** from 5-iodouracil in modest yield (38–53%) through the reaction of different alkynes. The synthesis also was performed with the uracil-PNA unit linked to an insoluble polymer support.⁵¹




Scheme 46

Under similar experimental conditions, Mintas *et al.* reported the synthesis of fourteen 5-alkynyl nucleoside analogues (**111**) in moderate to good yield from (*Z*)- and (*E*)-1-[4'-(*N*-phthalimido)-2'-butenyl]-5-iodouracil (Scheme 47).⁵³



Scheme 47

The Stille reaction has been also used by Mintas *et al.* to prepare 5-alkynyl derivatives.⁴³ They employed a set of tributylstannanes to prepare compounds **112** (R = H (44%), R = Me (33%) yields, Scheme 48).




Scheme 48

4. C(Uracil)-Heteroatom Bonds


a. C(Uracil)-N Bonds

Uracils linked to amines are perhaps the most studied heteroatom-substituted derivatives due to the fact that many synthetic and natural compounds of this type exhibit a diverse range of biological activities. The synthesis of 6-aminouracils from condensation of 2-cyanoacetic acid with urea and *N*-alkylureas was developed by Traube in 1900, but the reaction times were long and the yields poor. Recently, Devi and Bhuyan have improved this synthesis by performing the reaction without solvent under MW irradiation, obtaining good yields of 6-aminouracils (Scheme 49).⁵⁴




Scheme 49

Although the synthesis of many 6- and 5-(*N*-substituted) uracils has been developed in the 1970s,^{55,56} Wright and co-workers synthesized 6-(3-ethyl-4-methylaniliny)-3-alkyluracils (**114**) using a modified method from 6-aminopyrimidinone (**113**) with good yields (Scheme 50). Concomitant deprotection of the imido group occurred to give uracil directly.⁵⁷



Scheme 50

With a similar approach Spiccia *et al.*⁵⁸ have recently synthesized a PNA monomer attached to a ferrocenyl moiety. From dimethyl(ferrocenyl-methyl) ammonium salt **115**, the reaction with 5-aminouracil, uracil **116** was obtained in good yield (Scheme 51). From



Scheme 51

this compound the authors could prepare PNA monomer **117** (15% from **115**) and analyzed its electrochemical properties.

In a detailed study of the reaction of 6-chlorouracils with pyridines and 1-methylimidazole, Schmidt and Kindermann synthesized uracilates, uracilium salts **118**, and uracilybetaines **119** (Figure 3).⁵⁹ Reaction of 6-chloro-1,3-dimethyluracil with both heterocycles produced uracilium salts **118** in good yield (65–67%); derivatives of pyridine **118a** could be isolated with different anions ($\text{X} = \text{Cl}, \text{BPh}_4, \text{SbCl}_6, \text{I}, \text{OTf}$).




Figure 3

The use of 6-chloro-3-methyluracil could give mesomeric uracilyl betaines **119** (58–79%) for the reaction with the same amines (Figure 3). The reaction of **119** with 1,2-dichloroethane afforded 1,1'-(3,3'-(ethane-1,2-diyl)bis(1-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4,3-diyl))bis(4-(dimethylamino)pyridinium) (Figure 4) in 88% yield.





Figure 4

b. Synthesis of 5,6-Halogen Derivatives

In many cases, halogens as substituents in uracil derivatives lead to interesting biological activity and/or improved biological properties. Additionally, most of the substitution on the uracil nucleus is performed by substitution of the halogen on 5- or 6- (or 5,6-) halouracils by different functional groups. For this reason, various syntheses of 5- and 6-halouracils have been studied and the search for better conditions is of current interest. Several 5- and 6-halouracils have been synthesized using I₂/nitric acid, ICl, Br₂/(AcO)₂O, Br₂/H₂O, Br₂/DMF, Cl₂, NXS, CAN/halogen source, among others.^{60–62}

Recently, in a search for a more friendly approach to the iodination of pyrimidine-2,4-diones, Botta *et al.* synthesized 5-iodouracils from uracils (Scheme 52).⁶³ With *N*-iodosuccinimide (NIS) as the iodine source and three minutes MW irradiation, excellent yields of substitution products (97–98%) were obtained. The use of an unprotected nucleoside gave a yield of 65%. The authors tested the methodology in solid-supported chemistry and obtained good results, demonstrating the applicability of solid-phase organic synthesis for pyrimidones and nucleosides.



Scheme 52

c. C(Uracil)-Other Heteroatom Bonds


Using the methodology described in Section I.1 (Scheme 25), Kopp and Knochel also prepared 5-phenyl(methyl)sulfanyluracil and 5-trimethylsilyluracil in good yields (64–77%).²⁶ Doung and Louie (Section I.1, Scheme 14) synthesized 5-trimethylsilyl-6-alkyl-1,3-aryloracils with variable yields (17–83%).²¹ Suemune *et al.* (Section I.1, Scheme 20) have synthesized 5-trimethylsilyl- and 5-(methylthio)-2'-deoxyuridine in good yields (62–85%).²³

II. Fused Systems

1. C5-C6 Polycyclic Uracils

In a search for new uracils, Botta and Saladino *et al.* have synthesized fused pyrazole derivatives, through the reaction 5- and 6-substituted uracil with lithium trimethylsilyldiazomethane TMSC(Li)N₂ (**121**) or diazomethane.^{64,65} The authors used N1,N3-alkylated uracils and N3-alkylated uridines and found *umpolung* of reactivity of **121** in reaction with C6 derivatives.

When unsubstituted or 5-fluorouracils **120** (X = H, F; Y = H) were allowed to react with **121**, products **122** were obtained in good yield (Scheme 53); the formation of the products is attributed to nucleophilic attack at C6 and subsequent cyclization. When X = NO₂, CN or CHO, poor yields or no cyclic product **122** were obtained; however, in




Scheme 53

the case of the nitro compound using diazomethane instead of **121** gave an acceptable yield (39–45%) of 3a,7a-dihydro-4,6-dimethyl-7a-nitro- Δ^1 -pyrazolino[4,3-*d*]pyrimidin-5,7-dione regioisomer analogue to **122**.

With C6 substituted uracils (**120**, X = H), the reaction with **121** gave a mixture of **122** and pyrazolidine **123** (Scheme 53), due to attack of **121** to C5 instead of C6. The use of an isopropyl group at C6 allowed the preparation of **123** in good yield without the formation of **122**.

The reaction with halogen (other than fluorine) was only successful when X = Br, giving fused uracil derivatives **124** after loss of hydrogen bromide (Scheme 54).




Scheme 54


Bhuyan and co-workers have synthesized various complex fused uracils by means of different approaches.^{66–68} From *N,N*-dimethyl-5-formylbarbituric acid or 6-amino-1,3-dimethyluracil (**125**), pyrano- (**126a**) and pyrido[2,3-*d*]pyrimidine (**126b**) and (thio)oxazino[4,5*d*]pyrimidine (**127a** and **127b**) were prepared through a MW- assisted solid-phase (Scheme 55). Using maleimide or phenyl isothiocyanate as dienophiles, the authors showed that MW-assisted reactions gave better yields than conventional thermal reactions.⁶⁶

More recently, access to fused-spiro uracils (**129**) from 6-(*N,N*-dialkylamino)-5-formyluracil (**128**) and barbituric acids was demonstrated (Scheme 56).⁶⁷


A hypothetical mechanism was proposed but poorly demonstrated: after Knoevenagel condensation to give product **128a** an internal redox process occurred to generate a 1,6-dipole through a 1,5-H shift. Cyclization of the zwitterion formed gave the final product (Scheme 57).



Scheme 55



Scheme 56




Scheme 57


A stereoselective intramolecular hetero Diels-Alder reaction of compound **130** (Scheme 58), prepared from barbituric acids and salicylaldehyde, allowed the preparation of the fused system **131** in good yield with less than 5% of the *trans*-stereoisomer.⁶⁸

A similar approach was used by Gross *et al.*⁶⁹ to prepare **133** in very good yields (Scheme 59) from 1,3-dimethylbarbituric acid and aldehydes **132**. A domino Knoevenagel-hetero-Diels-Alder reaction was used and although a catalytic amount of CuI is required to activate the alkyne, the reactions have the advantage of using water as solvent.

An intermolecular variation of this hetero-Diels-Alder reaction was used to prepare pyrano[2,3-*d*]pyridine-2,4-dione **137** from 5-arylidene-1,3-dimethylbarbituric acid **136** and




Scheme 58



Scheme 59



enol ethers **135**. The goal of the authors was to prepare compounds **137** via a three-component one-pot synthesis, as shown in *Scheme 60*, giving the desired products in excellent yields.²



Scheme 60


Pyrano[3,2-*c*]pyrimidines-2,4-diones (**139**) have been synthesized in excellent yields (92–100%) via Pd-catalyzed reaction from 5-substituted-1,3-dimethyluracils (**138**) (*Scheme 61*).⁷⁰ The proposed mechanism involves an uncommon [1,3]aryloxy migration, followed by a 6-*endo dig* cyclization.

Using the same methodology described in Section I.1.a, (*Scheme 28*), Fustero and co-worker synthesized the 5,6-disubstituted uracils **140a** in order to prepare C5-C6 fused uracils **141** through an intramolecular olefin metathesis (*Scheme 62*).⁷¹ Compound **141a**




was obtained for $n = 0$ but by using different Ru catalysts, the authors could control the reaction obtaining **141a** ($n = 1$) or **141b** as a single product from **140a** ($n = 1$).

As shown in *Scheme 63*, the preparation of N1-C6 fused-uracils **142** was also possible from **140b**.




Through a well-known Pd-catalyzed arylation, Woodward *et al.* have synthesized uracils fused to a phenyl group in good yields from reaction of 2-bromobenzoic methyl esters (**143**) and substituted ureas (**144**) (*Scheme 64*).⁷² Both electron-donating as well as electron-withdrawing substituents in the phenyl moiety are tolerated. In addition, a regioselective reaction was obtained with monosubstituted ureas **144** ($R^1 = H$) to obtain N3 alkyl uracils **145** ($R^1 = H$).

From substituted phenylamines, Rivkin *et al.*⁷³ prepared analogues of **145**, mono and disubstituted in the phenyl ring, using *bis*(pentafluorophenyl) imidodicarbonate (**146**) in a




Scheme 64

solvent-free MW reaction; the yields were moderate to good (44–78%). The use of other heteroaromatic amines (**147**) allowed the authors to prepare compound **148** in moderate yield (Scheme 65). The synthesis of one disubstituted uracil was carried out from (2*E*)-3-amino-3-(4-bromophenyl)acrylonitrile in 84% yield.



Scheme 65

Xanthine (**151a**) or pteridine (**151b**) derivatives were obtained in moderate to good yields from 5,6-diamino-1,3-dimethyluracil (**149**). The synthetic sequence involves the preparation of enamines **150** from aldehydes and subsequent reaction with different one-carbon sources (triethyl orthoformate, orthoacetate or orthobenzoate). Depending on the ortho ester used, **151a** or **151b** was obtained (Scheme 66).⁷⁴




Scheme 66


Spiro[pyrimido-[4,5-*d*]quinoline-5,5'-pyrrolo[2,3-*d*]pyrimidine]pentanones (**154**) were synthesized by Bazgir *et al.* from 6-aminouracils (**152**) and 5-substituted indoline-2,3-diones (**153**) (Scheme 67), using water as solvent and 4-toluenesulfonic acid (4-TSA) as catalyst. The complex polyheterocyclic compounds **154** were obtained in very good yields (78–90%).⁷⁵

Although a mechanism could not be established with certainty, a possible route was proposed as depicted in Scheme 68.

It has been shown that the replacement of one carbon atom by nitrogen is a good strategy to obtain new potential antitumor compounds from known anticancer drug.^{76–78} In




Scheme 67



Scheme 68

line with this concept, Valderrama and Vásquez proposed the synthesis of *aza*-analogues of angucyclinone (Figure 5).

The authors synthesized quinones **156** in good yields from hydroquinone **155** and 6-amino-1,3-dimethyluracil using Ag_2O in CH_2Cl_2 at room temperature (Scheme 69).⁷⁹



Scheme 69

From compounds **156**, adducts **157** and **158** (Figure 6) were synthesized through a cycloaddition reaction with different dienes. Angucyclinone **159** analogues from **157** were finally obtained with good yields by mild hydrolysis with hydrochloric acid followed by oxidation with PCC of the alcohol intermediaries.




Figure 5





Figure 6

Using the versatile diazo compound **29** (see Scheme 34), Vasella *et al.* have also prepared different fused uracils through a Rh(II)-promoted reaction with different carbeneophiles by an intramolecular reaction.²⁰ Thermolysis of **29** in toluene gave 1:1 mixture 1*H*- and 2*H*-pyrazolo[4,3-*d*]uracil in 55% yield after deprotection with BBr₃ (Scheme 70).




Scheme 70

The reaction of **29** with 2-methoxypropene in the presence of Rh₂(AcO)₄ (Scheme 71) gave a cyclopropane derivative (*endo/exo*) from addition to the double bond, which after treatment with AlClMe₂ gave the cyclopenta[*d*]pyrimidine **160** in 55% yield. The reaction of dihydrofuran and dihydropyran afforded tricyclic uracils **161** and **162** in 51% and 88% yields respectively, through the same reaction sequence. The use of furan gave **163** in 73% yield without the need of Al(III) catalysis.


The acid-catalyzed intramolecular cyclization of **86** prepared from **29** (see Scheme 35), gave fused-diuracil **164** in 73% yield (Scheme 72).²⁰

2. Other Polycyclic Uracils

Uracil derivatives fused at C5-O4 or C6-N1 are less common than the fused uracils previously described; however, some efforts have also been made to develop new synthetic strategies for this family of compounds.




Scheme 71



Scheme 72


Robins and co-workers extended their work in the synthesis and the biological evaluation of furo[2,3-*d*]pyrimidin-2(3*H*)-one and synthesized derivatives **166** (Scheme 73).^{80,81} N1 substituted uracils were synthesized in moderate to good yields (51–83%) from 5-iodouracils **165** ($\text{R}' = \text{CH}_2\text{O}(\text{CH}_2)_2\text{OH}$), and different alkynes. The authors performed a Sonogashira coupling following a Cu(I)-promoted cyclization in a two step one pot procedure.⁸⁰ The synthesis of free uracil **166** ($\text{R}' = \text{H}$) was also done using the same approach, but in two consecutive steps and lower yields (step one 50–80%, step two 28–34%).

Access to pyrrolo derivatives **167** was possible from **166** ($\text{R}' = \text{CH}_2\text{O}(\text{CH}_2)_2\text{OH}$) after treatment with ammonia in methanol (Scheme 73).



Scheme 73

Compound **166** (R = H) was also synthesized; however, the yield was low (30%). This compound was used to prepare alkynyl derivatives **168** by performing a bromination and a Sonogashira coupling with different alkynes but again the yields were low (Scheme 74).⁸⁰



Scheme 74

III. Glossary

Cp: Cyclopenta-2,4-dien-1-ide

DIEA: *N,N*-Diisopropylethylamine

DMA: Dimethylacetamide

DMF: *N,N*-Dimethylformamide

DMSO: Dimethyl sulfoxide

dR: Deoxyuridine

FG: Functional group

LDA: Lithium diisopropylamide

L: Ligand

MW: Microwave

NXS: *N*-Halosuccinimide

PCC: Pyridinium chlorochromate

PNA: Peptide nucleic acid

$S_{RN}1$: Unimolecular Radical Nucleophilic Substitution

TABF: Tetrabutylammonium fluoride

THF: Tetrahydrofuran

TMSCl: Trimethylchlorosilane

TMS: Trimethylsilyl

TP: Thymidine phosphorylase

MNP: $(CH_3)_3C-N=O$

4-TSA: 4-Toluenesulfonic acid

Xantphos: 2,2'-Oxybis(2,1-phenylene)bis(diphenylphosphine)

Acknowledgements

This work was supported in part by the Agencia Córdoba Ciencia, the Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), SECYT, Universidad Nacional de Córdoba, and FONCYT, Argentina. J. I. B. gratefully acknowledges receipt of a fellowship from CONICET.

References

1. M. Lagoja, *Chem. Biodiv.*, **2**, 1 (2005).
2. A. Palasz, *Monatsh. Chem*, **139**, 1397 (2008).
3. D. Uraguchi, K. Yamamoto, Y. Ohtsuka, K. Tokuhisa and T. Yamakawa, *Appl. Catal., A*, **348**, 137 (2008).
4. R. Saladino, C. Crestini, A. T. Palamara, M. C. Danti, F. Manetti, F. Corelli, E. Garaci and M. Botta, *J. Med. Chem.*, **44**, 4554 (2001).
5. J. I. Bardagí and R. A. Rossi, *J. Org. Chem.*, **73**, 4491 (2008).
6. C. B. Reese and Q. Wu, *Org. Biomol. Chem.*, **1**, 3160 (2003).
7. Z. Guo, Y. Zhu, F. C. Tucci, Y. Gao, R. S. Struthers, J. Saunders, T. D. Gross, Q. Xie, G. J. Reinhartb and C. Chen, *Bioorg. Med. Chem. Lett.*, **13**, 3311 (2003).
8. M. W. Rowbottom, F. C. Tucci, P. J. Connors, Jr., T. D. Gross, Y. Zhu, Z. Guo, M. Moorjani, O. Acevedo, L. Carter, S. K. Sullivan, Q. Xie, A. Fisher, R. S. Struthers, J. Saundersa and C. Chen, *Bioorg. Med. Chem. Lett.*, **14**, 4967 (2004).
9. Y. Zhu, T. D. Gross, Z. Guo, P. J. Connors, Jr., Y. Gao, F. C. Tucci, R. S. Struthers, G. J. Reinhart, J. Saunders, T. K. Chen, A. L. K. Bonneville and C. Chen, *J. Med. Chem.*, **46**, 2023 (2003).
10. A. Dinsmore, P. M. Doyle, P. B. Hitchcock and D. W. Young, *Tetrahedron Lett.*, **41**, 10153 (2000).
11. C. G. Lee, S. Gowrisankar and J. N. Kim, *Bull. Korean Chem. Soc.*, **26**, 3, 481 (2005); *Chem. Abstr.*, **143**, 440139 (2005).
12. S. Nag, G.P. Yadav, P. R. Maulik and S. Batra, *Synthesis*, **6**, 911 (2007).
13. J. Cao and X. Huang, *J. Comb. Chem.*, **10**, 526 (2008).
14. S. Yano, H. Kazuno, N. Suzuki, T. Emura, K. Wierzba, J. Yamashita, Y. Tada, Y. Yamada, M. Fukushima and T. Asao, *Bioorg. Med. Chem.*, **12**, 3431 (2004).
15. S. Yano, H. Kazuno, N. Suzuki, T. Emura, K. Wierzba, J. Yamashita, Y. Tada, Y. Yamada, M. Fukushima and T. Asao, *Bioorg. Med. Chem.*, **12**, 3443 (2004).
16. F. Corelli, M. Botta, A. Lossani, S. Pasquini, S. Spadari and F. Focher, *Il Farmaco*, **59**, 987 (2004).
17. A. Fassihi, C. Velazquez and E. E. Knaus, *J. Heterocyclic Chem.*, **41**, 263 (2004).
18. A. Chacko, W. Qu and H. Kung, *J. Org. Chem.*, **73**, 13, 4874 (2008).
19. S. Kumar, V. Kumar, S. Singh and S. S. Chimni, *Tetrahedron Lett.*, **42**, 30, 5073 (2001).
20. F. Zhang, A. Kulesza, S. Rani, B. Bernet and A. Vasella, *Helv. Chim. Acta*, **91**, 1201 (2008).
21. H. A. Duong and J. Louie, *Tetrahedron*, **62**, 7552 (2006).
22. M. Botta, R. Saladino, G. Delle Monache, G. Gentile and R. Nicoletti, *Heterocycles*, **43**, 1687 (1996).
23. M. Aso, T. Kaneko, M. Nakamura, N. Koga and H. Suemune, *Chem. Commun.*, 1094 (2003).
24. J. D. White and J. Hansen, *J. Org. Chem.*, **70**, 1963 (2005).
25. N. Boudet, and P. Knochel, *Org. Lett.*, **8**, 17, 3737 (2006).
26. F. Kopp and P. Knochel, *Org. Lett.*, **9**, 9, 1639 (2007).

27. M. Médiébielle, J. Pinson and J. M. Savéant, *Tetrahedron Lett.*, **33**, 7351 (1992).
28. M. A. Ismail, H. H. Zoorob and L. Streckowski, *Arkivoc*, part x, 1 (2002).
29. D. Cech, R. Wohfeil, G. Etzold, *Nucleic Acid Res.*, **2**, 2183 (1975)
30. S. Fustero, J. Piera, J. F. Sanz-Cervera, S. Catalán and C. Ramírez de Arellano, *Org. Lett.*, **6**, 1417 (2004).
31. S. Fustero, S. Catalán, S. Flores, D. Jiménez, C. del Pozo, J. L. Aceña, J. F. Sanz-Cervera, and S. Mérida, *QSAR Comb. Sci.*, **25**, 753 (2006).
32. Y. Jiang, S. Chung, D. J., Krosky and J. T. Stivers, *Bioorg. Med. Chem.*, **14**, 5666 (2006).
33. R. Polo, J. M. Moretó, U. Schick and S. Ricart, *Organometallic*, **17**, 2135 (1998).
34. A. Spinella, T. Caruso, U. Pastore and S. Ricart, *J. Organomet. Chem.*, **684**, 266 (2003).
35. G. D. Sala, A. Artillo, S. Ricart and A. Spinella, *J. Organomet. Chem.*, **692**, 1623 (2007).
36. Barluenga's protocol based on fluoride ion. J. Barluenga, F. Andina, M. A. Fernández-Rodríguez, P. García-García, I. Merino and E. Aguilar, *J. Org. Chem.*, **69**, 7352 (2004).
37. Z. Guo, Y. Zhu, T. D. Gross, F. C. Tucci, Y. Gao, M. Moorjani, P. J. Connors, Jr., M. W. Rowbottom, Y. Chen, R. S. Struthers, Q. Xie, J. Saunders, G. Reinhart, T. K. Chen, A. L. K. Bonneville and C. Chen, *J. Med. Chem.*, **47**, 1259 (2004).
38. F. C. Tucci, Y. Zhu, Z. Guo, T. D. Gross, P. J. Connors, Jr., R. S. Struthers, G. J. Reinhart, J. Saunders and C. Chen, *Bioorg. Med. Chem. Lett.*, **13**, 3317 (2003).
39. Z. Guo, Y. Chen, C. Q. Huang, T. D. Gross, J. Pontillo, M. W. Rowbottom, J. Saunders, S. Struthers, F. C. Tucci, Q. Xie, W. Wade, Y. Zhu, D. Wua and C. Chen, *Bioorg. Med. Chem. Lett.*, **15**, 2519 (2005).
40. F. Amblard, S. P. Nolan, R. F. Schinazi and L. A. Agrofoglio, *Tetrahedron*, **61**, 537 (2005).
41. K. Pomeisl, A. Holý and R. Pohl, *Tetrahedron Lett.*, **48**, 3065 (2007).
42. B. Y. Oquare and J. S. Taylor, *Bioconjugate Chem.*, **19**, 2196 (2008).
43. T. Gazivoda, S. Raić-Malić, M. Marjanović, M. Kralj, K. Pavelić, J. Balzarini, E. De Clercq and M. Mintas, *Bioorg. Med. Chem.*, **15**, 749 (2007).
44. For reviews, see: R. A. Rossi, A. B. Pierini, A. B. Peñéñory, *Chem. Rev.* **103**, (2003), and R. A. Rossi, *Photoinduced Aromatic Nucleophilic Substitution*; Chapter 16, "Synthetic Organic Photochemistry", p 495, Marcel Dekker, New York (2005).
45. H. Wójtowicz-Rachel, M. Migas and H. Koroniak, *J. Org. Chem.*, **71**, 8842 (2006).
46. M. Médiébielle, M. A. Oturan, J. Pison and J. M. Savéant, *Tetrahedron Lett.*, **34**, 3409 (1993).
47. M. Médiébielle, M. A. Oturan, J. Pison and J. M. Savéant, *J. Org. Chem.*, **61**, 1331 (1996).
48. S. S. H. Davarani, N. S. Fumani, H. Arvin-Nezhad and F. Moradi, *Tetrahedron Lett.*, **49**, 710 (2008).
49. K. Sonogashira, Y. Tohda and N. Hagihara, *Tetrahedron Lett.*, 4467 (1975).
50. F. W. Hobbs Jr., *J. Org. Chem.*, **54**, 3420 (1989).
51. R. H. E. Hudson, G. Li and J. Tse, *Tetrahedron Lett.*, **43**, 1381 (2002).
52. F. Wojciechowski and R. H. E. Hudson, *Nucleos. Nucleot. Nucl.*, **26**, 1199 (2007).

53. T. Gazivoda, S. Raić-Malić, V. Krištafor, D. Makuc, J. Plavec, S. Bratulić, S. Kraljević-Pavelić, K. Pavelić, L. Naesens, G. Andrei, R. Snoeck, J. Balzarini and M. Mintas, *Bioorg. Med. Chem.*, **16**, 5624 (2008).
54. I. Devi and P. J. Bhuyan, *Tetrahedron Lett.*, **46**, 5727 (2005).
55. C. Zhi, Z. Long, J. Gambino, W. Xu, N. C. Brown, M. Barnes, M. Butler, W. LaMarr and G. E. Wright, *J. Med. Chem.*, **46**, 2731 (2003).
56. N. C. Brown, J. Gambino and G. E. Wright, *J. Med. Chem.*, **20**, 1186 (1977).
57. C. Zhi, Z. Long, A. Manikowski, N. C. Brown, P. M. Tarantino, K. Holm, E. J. Dix, G. E. Wright, K. A. Foster, M. M. Butler, W. A. LaMarr, D. J. Skow, I. Motorina, S. Lamothe and R. Storer, *J. Med. Chem.*, **48**, 7063 (2005).
58. G. Gasser, M. J. Belousoff, A. M. Bond and L. Spiccia, *J. Org. Chem.*, **71**, 7565 (2006).
59. A. Schnudt and M. K. Kindermann, *J. Org. Chem.*, **62**, 3910 (1997).
60. J. Asakura and M. Robins, *J. Org. Chem.*, **55**, 4928 (1990).
61. M. Elshehry, J. Balzarini and C. Meier, *Synthesis*, 841 (2009).
62. S. Boncel, A. Gondela and K. Walczak, *Curr. Org. Synth.*, **5**, 365 (2008) and reference therein.
63. L. Paolini, E. Petricci, F. Corelli and M. Botta, *Synthesis*, 1039 (2003).
64. R. Saladino, L. Stasi, C. Crestini, R. Nicoletti and M. Botta, *Tetrahedron*, **53**, 7045 (1997).
65. R. Saladino, L. Stasi, R. Nicoletti, C. Crestini and M. Botta, *Eur. J. Org. Chem.*, 2751 (1999).
66. I. Devi, H. N. Borah and P. J. Bhuyan, *Tetrahedron Lett.*, **45**, 2405 (2004).
67. B. Baruah and P. J. Bhuyan, *Tetrahedron Lett.*, **50**, 243 (2009).
68. I. Devi and P. J. Bhuyan, *Tetrahedron Lett.*, **45**, 7727 (2004).
69. M. J. Khoshkholgh, S. Balalaie, H. R. Bijanzadeh, F. Rominger and J. H. Gross, *Tetrahedron Lett.*, **49**, 6965 (2008).
70. K. C. Majumdar, B. Sinha, B. Chattapadhyay and K. Ray, *Tetrahedron Lett.*, **49**, 4405 (2008).
71. S. Fustero, S. Catalán, J. Piera, J. F. Sanz-Cervera, B. Fernández and J. L. Aceña, *J. Org. Chem.*, **71**, 3910 (2006).
72. M. C. Willis, R. H. Snell, A. J. Fletcher and R. L. Woodward, *Org. Lett.*, **8**, 22, 5089 (2006).
73. S. M. Chicetti, S. P. Ahearn and A. Rivkin, *Tetrahedron Lett.*, **49**, 6081 (2008).
74. O. I. El-Sabbagh, M. E. El-Sadek, S. El-Kalyoubi and I. Iamail, *Arch. Pharm. Chem. Life Sci.*, **340**, 1 (2007).
75. R. Ghahremanzadeh, S. C. Azimi, N. Gholami and A. Bazgir, *Chem. Pharm. Bull.*, **56**, 1617 (2008).
76. H. Lee, S.-I. Lee, and S.-I. Yang, *Bioorg. Med. Chem. Lett.*, **8**, 2991 (1998).
77. G. Tudor, P. Gutierrez, A. Aguilera-Gutierrez, and E. A. Sausville, *Biochem. Pharmacol.*, **65**, 1061 (2005).
78. J. A. Valderrama, M. F. González, P. Colonelli, and D. Vásquez, *Synlett*, **2006**, 2777.

79. J. A. Valderrama and D. Vásquez, *Tetrahedron Lett.*, **49**, 703 (2008).
80. Z. Janeba, J. Balzarini, G. Andrei, R. Snoeck, E. Clercq and M. J. Robins, *J. Med. Chem.*, **48**, 4690 (2005).
81. Z. Janeba, J. Balzarini, G. Andrei, R. Snoeck, E. Clercq and M. J. Robins, *Can. J. Chem.*, **84**, 580 (2006).